These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24909440)

  • 21. The newer fluoroquinolones.
    Bolon MK
    Infect Dis Clin North Am; 2009 Dec; 23(4):1027-51, x. PubMed ID: 19909896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital.
    Gallini A; Degris E; Desplas M; Bourrel R; Archambaud M; Montastruc JL; Lapeyre-Mestre M; Sommet A
    J Antimicrob Chemother; 2010 Dec; 65(12):2650-7. PubMed ID: 20876240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintaining fluoroquinolone class efficacy: review of influencing factors.
    Scheld WM
    Emerg Infect Dis; 2003 Jan; 9(1):1-9. PubMed ID: 12533274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The rapid development of fluoroquinolone resistance in M. tuberculosis.
    Ginsburg AS; Woolwine SC; Hooper N; Benjamin WH; Bishai WR; Dorman SE; Sterling TR
    N Engl J Med; 2003 Nov; 349(20):1977-8. PubMed ID: 14614180
    [No Abstract]   [Full Text] [Related]  

  • 25. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance.
    Ferrara AM
    Infection; 2005 Jun; 33(3):106-14. PubMed ID: 15940410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The newer fluoroquinolones.
    O'Donnell JA; Gelone SP
    Infect Dis Clin North Am; 2004 Sep; 18(3):691-716, x. PubMed ID: 15308282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment.
    Zaytoun OM; Vargo EH; Rajan R; Berglund R; Gordon S; Jones JS
    Urology; 2011 May; 77(5):1035-41. PubMed ID: 21420152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluoroquinolone-resistant Streptococcus pneumoniae.
    Pletz MW; Fugit RV; McGee L; Glasheen JJ; Keller DL; Welte T; Klugman KP
    Emerg Infect Dis; 2006 Sep; 12(9):1462-3. PubMed ID: 17073107
    [No Abstract]   [Full Text] [Related]  

  • 29. Molecular mechanisms of fluoroquinolone resistance.
    Chen FJ; Lo HJ
    J Microbiol Immunol Infect; 2003 Mar; 36(1):1-9. PubMed ID: 12741725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluoroquinolone resistance trends and animal drug use: a retrospective analysis.
    Radostits OM
    Int J Infect Dis; 2004 May; 8(3):187-9; author reply 190-2. PubMed ID: 15109595
    [No Abstract]   [Full Text] [Related]  

  • 31. The magnitude of the association between fluoroquinolone use and quinolone-resistant Escherichia coli and Klebsiella pneumoniae may be lower than previously reported.
    Bolon MK; Wright SB; Gold HS; Carmeli Y
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1934-40. PubMed ID: 15155181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial resistance in internal medicine wards.
    Menichetti F; Tagliaferri E
    Intern Emerg Med; 2012 Oct; 7 Suppl 3():S271-81. PubMed ID: 23073868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of several fluoroquinolones and beta-lactams in terms of their capability to restrict the selection of fluoroquinolone-resistant Salmonella: in vitro models.
    Cebríán L; Rodríguez JC; Escribiano I; Royo SG
    APMIS; 2007 Dec; 115(12):1376-82. PubMed ID: 18184408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluoroquinolone resistance: overuse of fluoroquinolones in human and veterinary medicine can breed resistance.
    Piddock LJ
    BMJ; 1998 Oct; 317(7165):1029-30. PubMed ID: 9774285
    [No Abstract]   [Full Text] [Related]  

  • 35. Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit.
    Aubert G; Carricajo A; Vautrin AC; Guyomarc'h S; Fonsale N; Page D; Brunel P; Rusch P; Zéni F
    J Hosp Infect; 2005 Feb; 59(2):83-9. PubMed ID: 15620440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones.
    Wispelwey B
    Clin Infect Dis; 2005 Jul; 41 Suppl 2():S127-35. PubMed ID: 15942879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emergence of fluoroquinolone resistance in Escherichia coli isolates at the department of clinical hematology.
    Zemkova M; Kotlarova J; Merka V; Cermak P; Vlcek J; Jebavy L
    New Microbiol; 2007 Oct; 30(4):423-30. PubMed ID: 18080678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluoroquinolone-resistant Salmonella Paratyphi A.
    Adachi T; Sagara H; Hirose K; Watanabe H
    Emerg Infect Dis; 2005 Jan; 11(1):172-4. PubMed ID: 15714664
    [No Abstract]   [Full Text] [Related]  

  • 39. Use of fluoroquinolones: practical considerations.
    Ponte CD; Fisher MA
    Am Fam Physician; 1993 Apr; 47(5):1243-9. PubMed ID: 8465719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluoroquinolone benchmarking in relation to pharmacokinetic and pharmacodynamic parameters.
    Paladino JA; Callen WA
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():43-7. PubMed ID: 12702703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.